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 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel 
coronavirus that causes coronavirus disease 2019 (COVID-19) and has escalated, 
becoming a pandemic in early 2020. Multiple testing modalities have been developed to 
detect this virus including RT-PCR, antigen, and serology testing. RT-PCR testing is the 
clinical gold standard and is used for diagnostic purposes of current infections. Antigen 
testing is rapid and requires significantly less equipment, but lacks the sensitivity of RT-
PCR testing. Serology assays detect antibodies raised against SARS-CoV-2, so only 
detect prior exposure. It is important to note that use of antibody tests may also detect 
prior asymptomatic infections. For these reasons, it is imperative that all testing 
modalities be continuously developed and improved to better our understanding of 
disease transmission, helping to inform and change infection control policies and 
protecting both employees in the workplace and patients.  
We aim to quantify the seroprevalence of anti-SARS-CoV-2 IgG in the healthcare 
workers at Boston Medical Center, including those with asymptomatic infections. Our 
results show an overall seroprevalence of 5.5% with an asymptomatic seroprevalence of 
1.8%. High risk groups include those who are obese, smokers, and Hispanic/LatinX. 
Experiencing some symptoms was associated with a higher risk of seropositivity, as was 
lack of social distancing amongst coworkers.  
 
 v 
In a separate study, we aim to assess the direct antigen rapid tests (DART) created by 
E25Bio in patients seeking care at Boston Medical Center. This study has been 
significantly limited by number of participants, as recruitment has been paused during 
both COVID-19 surges in Boston, MA. The current data shows poor positive agreement 
between DART and RT-PCR, but acceptable negative agreement.  
Each testing modality works to fill in the gaps of knowledge that still persist around 
SARS-CoV-2. Each of these testing types provides a unique piece of information and 
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Chapter 1: COVID-19 Overview 
The first cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2) infection were discovered in Wuhan, China during December 2019. This 
infection was named Coronavirus disease 2019 (COVID-19) (1). Throughout early 2020, 
SARS-CoV-2 spread rapidly worldwide and was declared a pandemic in March 2020 by 
World Health Organization (WHO). As of March 13, 2021, at least 118,754,336 people 
have been infected, and 2,634,370 have died (2). Within the United States (US)  alone, it 
has infected at least 29,113,651 people, causing the death of at least 529,301 of those (3). 
Although there is limited data available, it is estimated that at least 444,256 health care 
workers (HCW’s) in the US have been infected, causing the death of 1,453 (4).  
Although SARS-CoV-2 originated in Wuhan, China, it quickly spread across the 
world. The United States reported its first case on January 20, 2020 (5), and 
Massachusetts (MA) on March 2, 2020 (6). Boston, MA hosted a Biogen conference 
during February 2020, which acted as a superspreading event and caused the positivity 
rates to increase rapidly (7). Boston Medical Center (BMC) is the largest safety net 
hospital in Boston and received a significant portion of the areas COVID-19 patients 
during the first surge starting in March 2020. In an effort to stop the virus, drastic public 
health measures were taken across the world, including stay at home orders and 
quarantine regulations.  Regardless, the virus continued to spread rapidly. Although cases 
started to decline throughout the summer of 2020, another surge happened in late 
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November-February, 2021 (8), and BMC saw an increase in SARS-CoV-2 positivity 
amongst its patients and HCW’s.  
 
COVID-19 Structure 
 SARS-CoV-2 belongs to the family of betacoronavirus 2B and has over 100 
different strains which each have different mutations, each mutation affecting the 
infectivity rate of the strain (1). This virus is the largest known RNA virus and is 
comprised of 4 main proteins: the nucleocapsid, membrane, spike, and envelope proteins. 
The nucleocapsid protein forms the capsid or outer protective coating of the virus and 
covers the genetic material, while the spike protein mediates host cell entry. The other 
proteins are largely structural (1).   
The basic reproduction number, R0 is the average number of infections each 
infectious individual may cause in a population with no previous exposure (9, 10). For 
SARS-CoV-2, the R0 is between 2-4. Using the equation 1-1/ R0, the immunity threshold 
can be calculated, which gives the approximate percent of the population that needs to 
have immunity to stop the spread of the virus. In this case the herd immunity threshold is 
estimated to between 67-75% (9-11). Development of a vaccine began taking place at 
multiple companies, in an effort to overcome the pandemic. Achieving herd immunity 
would mean that approximately 67-75% of the population becomes immune to the virus 
through either vaccination or infection, preventing the virus from continually spreading 
(9, 10, 12).  
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Multiple companies are in a race to develop vaccines to protect against SARS-
CoV-2 and, as of March 2021, Pfizer, Moderna, and Johnson & Johnson have received 
Emergency Use Authorizations (EUA) from the Food and Drug Administration 
(FDA)(13, 14). Vaccine administration began in late December, 2020 with an emphasis 
on vaccination in critical communities including healthcare workers, non-healthcare 
essential workers, people over the age of 65, and adults with multiple comorbidities(15).  
 
 
Host Immune Response  
After endocytosis into the host cell of the virus occurs, the host antiviral response 
can be inhibited, as the virus may block production pathways of type 1 interferons, which 
typically work to induce antiviral actions to host cells (16, 17). In addition, infection by 
SARS-CoV-2 also increases the amount of pro-inflammatory cytokines produced (16).  
Only when the virus enters the host tissue cells does antibody production begin, 
introducing detectable antibodies into the bloodstream that are indicative of past 
exposure. Proteins from SARS-CoV-2 are presented to CD8+ T cells by major 
histocompatibility complexes (MHC) class I, causing the CD8+ T cells to divide. This 
produces two types of T cells: effector and memory. MHC class II molecules are found 
on antigen presenting cells (APC) and present the viral proteins to CD4+ T cells. B cells 
can be activated by either MHC class II molecules from APC’s or from the virus itself 
(16, 18). Once activated, B cells begin clonal expansion, which produces antibody 
producing cells. IgM is secreted from short lived plasma cells, providing a rapid response 
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only. As the B cells continue to develop, the immunoglobulin undergoes recombination, 
creating immunoglobulin (Ig) with a higher affinity for the antigen. These high affinity Ig 
include immunoglobulin G (IgG), which are longer lasting and can potentially provide 
lasting immunity to the virus (16, 18, 19).  
In the case of SARS-CoV-2, IgM is generally produced between 3-14 days after 
the beginning of symptoms and only remains in detectable amounts for approximately 4 
weeks in the blood (16, 20, 21). IgG can be present in blood as early as 9 days after the 
beginning of symptoms and remains present in blood at detectable levels for at least 90 
days prior to declining but is variable from person to person. The length and level of 
antibody response differs between individuals, depending on disease severity, age, sex, 
race, length of symptom duration, and certain comorbid conditions (20, 21).   
A study from Guangzhou, China showed evidence of both IgM and IgG 
production in the first week post symptom onset, with IgG level eclipsing IgM level 
during the second week post symptom onset and IgM levels plateauing during week 3 for 
patients requiring medical care in the intensive care unit (ICU) (22). However, in patients 
with confirmed COVID-19 who did not require ICU stay antibody levels showed a 
similar pattern with the exception of IgM levels decreasing during week 3 (22). IgM 
against both the nucleoprotein and the spike protein, as well as the IgG against the 
nucleoprotein were all significantly higher in the ICU patients, while the spike IgG was 
significantly higher in patients not requiring ICU care(22). Additionally, it has been noted 
that IgM production is initially delayed in patients with severe disease progression and 
does not equate to IgM levels in non-severe cases until after 14 days post symptom onset 
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(23). After this time point, both IgM and IgG levels in severely ill patients are 
significantly higher than those in mildly ill patients (24). 
In another study, it was shown that 52 of the 72 seropositive participants IgG 
levels started to begin to decline by 100 days post symptom onset (25), although these 
antibodies remain present at detectable levels past that (26). Interestingly, the 20 
participants who had a sustained IgG level, experienced fewer total days of COVID-19 
symptoms than the participants with declining IgG levels (9.5 and 15.5 days, 
respectively) (25). Future studies focusing on longevity of antibody presence will help to 




Symptoms and Comorbidities  
Persons infected with SARS-CoV-2 commonly experience symptoms including a 
dry cough, fever, shortness of breath, fatigue, myalgia, headache, dyspnea, and sore 
throat (27, 28). Although less likely, they may also experience some of the less common 
symptoms such as anosmia and ageusia (loss of smell and taste), nausea and vomiting, 
and diarrhea (27, 28). Within 7 days of exhibiting symptoms, patients may experience 
serious complications such as acute respiratory distress syndrome (ARDS), pneumonia, 
acute liver injury, cardiovascular problems, thromboembolism, neurologic complications, 
and inflammation, all of which are indicative of severe disease and may lead to death (27, 
29, 30).  
 
6 
Mildly symptomatic patients generally recover within 2 weeks, while patients 
who experience a more severe disease course can take over 3 months to recover, with 
frequent instances of long-term respiratory distress (31). Individuals can begin 
transmitting the disease 2-3 days prior to appearance of symptoms, and are the most 
infectious nearly 1 day prior to appearance of symptoms (32).  
People at higher risk for developing severe disease include the elderly, as well as 
those with some chronic conditions such as cancer, chronic kidney disease (CKD), 
chronic obstructive pulmonary disease (COPD), heart failure, coronary artery disease 
(CAD), obesity, pregnancy, sickle cell disease, type 2 diabetes mellitus, and individuals 
who smoke tobacco (30, 33, 34). COVID-19 patients with these pre-existing medical 
conditions are more likely to require hospitalization, admittance to the intensive care unit 
(ICU) of the hospital, breathing assistance including supplemental oxygen, intubation, 
and death (27, 30). 
Health care workers are among a high-risk population for both getting infected 
with the virus and transmitting it, as they are working one on one with patients in 
numerous settings. Some infected people remain asymptomatic throughout the duration 
of their disease course and it has been shown that asymptomatic individuals may transmit 
the disease for up to 21 days (32). For these reasons, it is important to have the tools to 






Testing for COVID-19 
Since the onset of the COVID-19 pandemic, many testing platforms have been 
developed. There are a multiple assay types including RT-PCR, ELISA, antigen, and 
serological testing. Each type has a variable clinical indication, sample source and 
provides a result that has different clinical utility (35). Respiratory tests most commonly 
use nasopharyngeal (NP), oropharyngeal (OP), and/or anterior nares (AN) specimens. 
They are used to test for the viral RNA present within the respiratory system at the time 
of the specimen collection, so results from this type of test diagnoses current SARS-CoV-
2 infection. The clinical gold standard, reverse transcriptase polymerase chain reaction 
(RT-PCR) assays each use respiratory specimens (36). RT-PCR testing works by 
amplifying and tagging the viral genetic material found in the patient specimen, finally 
quantifying the level of infection by measuring the fluorescent tags on the amplified 
genes (35). Although, the actual RT-PCR test itself takes 24-48 hours to run, however it 
can take over one week depending on location and testing capabilities. Another limitation 
with these types of testing is that NP and OP swab specimens can only be collected by 
clinical staff, due to risk associated with the procedure. Additionally, it is important to 
note that RT-PCR testing only provides information about current infection status. 
Antigen testing can use either respiratory or blood specimens and can provide a 
result in 30 minutes or less. It is advantageous because it can provide a clinical result on-
site and with very minimal specialized equipment(37). Multiple sources have called for 
these types of tests to be marketed as “at home” tests, as they can be used with AN 
specimens, which can be done by the person needing the test and without the clinical 
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setting. In addition, antigen testing is much less expensive than RT-PCR testing and may 
provide opportunity to have the general public testing with much more frequency, 
catching more infections before they cause symptoms, and therefore limiting viral spread 
(38-42). However, there are concern around antigen testing regarding low sensitivity, 
which will provide false-negative results (42, 43). For this reason, antigen tests provide 
the most reliable results when used in symptomatic individuals (44).  
Antibody tests can also be performed to detect if the body has had an immune 
response to SARS-CoV-2. These blood tests detect antibodies including immunoglobulin 
G (IgG) and immunoglobulin M (IgM), which can help determine if a person has been 
exposed to SARS-CoV-2, including both symptomatic and asymptomatic disease 
courses, and possibly the vaccine. Understanding seroprevalence rates of antibodies 
against SARS-CoV-2 will help us understand SARS-CoV-2 and its asymptomatic 
infection rate, assessing antibody levels over a period of time can inform transmission, 
infection control measures, and antibody longevity, as well as potential immunity to the 










Chapter 2: Studies 
Research Role of Testing 
RT-PCR testing is used for diagnosis of acute infections of SARS-CoV-2, but is 
largely limited by specimen collection time, location, and technique. While this type of 
testing is most useful for diagnosing for symptomatic individuals or those who have had 
known exposure to SARS-CoV-2. Broad testing for seroprevalence of antibodies against 
SARS-CoV-2 will capture the total number of people infected, even if they had minimal 
or no symptoms during their infection. To help determine transmission and infection rates 
of this virus, it is imperative to know true positivity rates.  
 
SIG-COVID 
In this study, we aim to understand the seroprevalence among healthcare workers 
at Boston Medical Center, the largest safety net hospital in the northeast.  Healthcare 
workers spend a large amount of time in a high-risk setting, caring directly for infectious 
patients and handling their specimens. Better information about disease transmission can 
help to inform and change infection control policies at the hospital, protecting both the 
employees in the workplace and patients from nosocomial infections.  
 
E25Bio DART 
 As previously mentioned, there are significant limitations with relying only on 
RT-PCR testing. In an attempt to make testing available to an increased number of 
people, E25Bio has developed a Direct Antigen Rapid Test (DART) for SARS-CoV-2 
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and is aiming to achieve Food and Drug Administration (FDA) approval for the test. This 
will provide incredibly fast results using AN specimens, allowing anyone from first 
responders to patients to quickly take a specimen and get a rapid result in 15 minutes. 
Achieving widespread use of rapid tests can help to inform people on their current 
infectivity, targeting asymptomatic people and promoting quarantine and thus lessening 
the public health burden. We aim to test patients at Boston Medical Center using the 
DART device.  
 
SARS-CoV-2 Testing 
Each testing modality mentioned here will work to fill in the gaps of knowledge 
that still persist around SARS-CoV-2. Rapid antigen testing provides the possibility of 
extending inexpensive point of care testing to high-risk individuals, primary care offices, 
first responders, and even the general public for at-home use. Antibody testing only 
detects past infections, but is able to catch asymptomatic infections, and in the long term 
will provide information on immunity and antibody durability. Finally, RT-PCR testing is 
the gold standard diagnostic tool for current infections and will be the comparator results 





SIG-COVID Baseline Study 
Study Design and Participants 
 All healthcare workers who worked on the Boston Medical Center campus during 
the first surge of COVID-19 (March 13, 2020 – May 31st, 2020) and who were over 18 
years old were invited to enroll in this study. They were notified via email, an alert on 
BMC’s website, informational posters around the hospital, and discussion at both 
departmental meetings and hospital-wide town halls. Interested participants were given a 
link to a REDCap survey to screen for eligibility and, if they met eligibility criteria, went 
on to a second webpage where they provided electronic consent and a detailed 
questionnaire including sociodemographic and occupational characteristics, 
comorbidities, smoking history, possible and confirmed COVID exposure and diagnosis, 
COVID-19 symptoms, workplace exposure, and infection prevention and control 
measures. Lastly, the participants scheduled and participated in a blood draw between 
July 13th-26, 2020 at BMC. All REDCap forms were available in English, Spanish, and 
Haitian-Creole, the three most prominent languages spoken amongst BMC staff. This 
project was approved by the Institutional Review Board (IRB) and the COVID-19 







SARS-CoV-2 Antibody Measurement 
After the blood was drawn, it was transported via the pneumatic tube system at 
BMC to the clinical pathology laboratory and run on the Abbott Architect i2000 
instrument using the Abbott SARS-CoV-2 IgG assay per manufacturer’s instructions 
(SARS-CoV-2 IgG; Abbott Laboratories, Abbott park, IL). This assay is a 
chemiluminescent microparticle immunoassay (CMIA) for qualitative detection of IgG 
antibody in human serum against the nucleocapsid (N) protein of SARS-CoV-2.  
In this automated assay, participant serum, paramagnetic particles coated with 
SARS-CoV-2 antigen, and an assay diluent are incubated together during which the 
antibodies present in the serum sample bind to the antigen. This mixture is washed, and a 
fluorescent conjugate is added and incubated. Lastly, a pre-trigger and then a trigger 
solution will be added, and the resulting luminescence will be read and resulted as a 
relative light unit (RLU). The RLU of the samples is divided by the RLU of the 
calibrator, providing an index value.  
Each sample result was interpreted as positive (index value >= 1.4), or negative 
(index value <1.4) based on values reported by the instrument. Qualitative results were 
returned to each participant using REDCap. 
Quality control (QC) was run twice daily through the duration of the study to determine 
low and high QC levels. The inter-day coefficients of variation (CV) were 14.30% and 







All data from the Abbott i2000 was imported into REDCap. All questionnaire 
responses completed in Spanish and Haitian-Creole were manually translated to English. 
Frequency distributions were examined for normality. Continuous variables were 
represented with mean and standard deviation, while categorial variables were 
represented as counts. The association between categorical variables was tested using 
Chi-Square or Fisher’s Exact test, depending on sample size. The association between 
continuous variables was tested using a Student’s T-test. Missing data of less than five 
percent was excluded from analysis. P-values were considered significant when P < 0.05. 
Relative risk was calculated for demographic variables. All analyses were performed in R 
Version R-1.3.1056 (R Foundation for Statistical Computing).  
 
DART 
Study Design and Participants 
 Eligibility criteria included any patient over 18 who presented to the emergency 
department at Boston Medical Center with 6 days or fewer of COVID-19 symptoms. 
These patients were approached by the emergency department physician or physician’s 
assistant and were invited to enroll in the study. Interested participants signed an 
informed consent and an additional NP (prior to December 14th, 2020) or AN swab (on or 
after December 14th, 2020) was collected. This project was approved by the Institutional 
Review Board (IRB) and the COVID-19 Research Review Committee at Boston 




Specimen Collection and Testing 
An additional swab (either NP or AN) was obtained from the opposite nostril of 
the clinical swab and was transferred to the research lab for testing on the DART device. 
This test is a lateral flow immunoassay that provides qualitative results of SARS-CoV-2 
presence in NP or AN specimen from patients. 
This type of assay works when the specimen of interest is placed onto the sample 
pad at one end of the cassette. Capillary action causes the sample to proceed down the 
cassette, immediately coming into contact with antibodies specific to the analyte that 
have been conjugated to colored microparticles, continually migrating down the strip. 
The test line will change color when contact occurs with the analyte, while the control 
strip will change color if the sample reaches it at all. DART provides results in as little as 
15 minutes.  
 
Device #1:  
The NP swab was transported in 300uL of viral transport media (VTM) through 
the pneumatic tube system from the hospital to the clinical chemistry laboratory. The 
specimen was centrifuged for 1 minute at low speed to gather all liquid at the bottom of 
the tube. A dipstick was gently dropped into the vial and photos were taken at 15 and 30 
minutes. If one line (the control) appeared on the dipstick, the result was considered 
negative. If two lines appeared on the dipstick, the result was considered positive. The 
result was recorded in REDCap. The remaining VTM and swab were stored at -80C.  
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Device #2:  
The AN swab was transported in 300uL of elution buffer through the pneumatic 
tube system from the hospital to the clinical chemistry laboratory. 50uL of the elution 
buffer from the swab was pipetted into a new collection tube, and 50uL provided buffer 
solution was added. This solution was pipetted gently before 100uL was placed into the 
collection well of the new DART device, at which point a timer was started. A photo was 
taken at 15 minutes. The result was interpreted as positive or negative and recorded in 
REDCap. The remaining elution buffer and swab were stored at -80C. 
 
Device Changes 
There are two major differences between the first and second DART device. The 
first device was a dipstick that was placed upright in elution buffer containing a patient 
specimen, where it tested for the presence of the spike protein antigen of SARS-CoV-2. 
The second device was a cassette that required 100uL elution buffer placed onto the 
samples pad, where it then tested for the presence of the nucleocapsid protein antigen of 
SARS-CoV-2. This change was initiated by the company due to other studies that they 
had performed that indicated that N-protein was more sensitive and specific, thus 








 Medical record data extraction from the BMC EPIC electronic medical record 
(EMR) was carried out. Information gathered included demographics, RT-PCR results, 
lab values, and co-morbidity data. RT-PCR data included time and date of collection, 
time of result, instrument, result time, and cycle threshold (CT) values. Lab values 
included Ferritin, C reactive protein (CRP), white blood cell count, erythrocyte 
sedimentation rate, platelets, procalcitonin, lactate dehydrogenase, and D-dimer. 
Demographics included data on sex, race, ethnicity, body mass index, and age. All data 
was collected and stored in REDCap.  
 
Statistical Analysis  
All data stored in REDCap was exported to R. Categorical data was represented 
as counts and percentages, and association between variables was calculated using 
Fisher’s Exact test. P values were considered significant when P < 0.05. All analyses 









Of the BMC HCW’s who worked on campus during the surge and were over 18 
years old (n = 4,538), 2,218 completed the initial screening agreement. 1,989 of these 
completed the informed consent. Of these, 246 individuals had incomplete study records 
due to not completing the survey or not getting their blood drawn. A total of 1,743 























Of the 1,743 participants, the mean age was 38.9 years old (SD: 15.2 years) and 
mostly female (74.8%). Nearly half of the participants were overweight or obese 
(49.57%) and most were white (75.5%) with 9.30% Asian, 8.26% Black, and 8.23% 
Hispanic. 
The majority of the participants were doctors (30.0%) or nurses (41.1%), while 
non-patient facing allied health, patient facing allied health, and administrative staff made 
up 6.4%, 12.7%, and 8.3% respectively (Table 1).  
Of the 1,743 participants, 95 (5.5%) were positive for SARS-CoV-2 IgG. 
Although no correlation was shown between sex, age, or race, significant associations 
were shown between weight and ethnicity. Individuals who identified as obese had a 
1.97-fold higher risk of having IgG (p=0.02), while participants who were 
Hispanic/LatinX had a 1.79-fold higher risk (p=0.05) (Table 1).  
Although both patient facing allied health and nursing staff were more likely to 






Table 1. Study Demographics 











































3 (0.2%) 0 3 (100%)  0 (0.00-
NaN**) 
Age (years)    p < 
0.001†* 
 












































>69 11 (0.6%) 0 11 (100%)  0.00 (0.00-
NaN**) 
BMI    0.02†*  
Underweight (<18.5 
kg/m2) 





























Hispanic/LatinX    0.05†  
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† Fisher’s Exact Test, otherwise, Chi Squared 
* Statistically significant when p-value < 0.05 
**NaN is Not a Number, unable to divide by 0 
Column percentages may not always add up to 100% due to missing data. Missing data not included in analysis ranged 
from 0.11-1.32% 
Administrative: Director, Supervisor, Manager, Chairs, Admission personnel 
Allied Health – Nonpatient facing: Lab personnel, Lab Technologist, Radiology 
Allied Health – Patient facing: Technologist, Medical Assistant, Speech Pathologist, Team Leader, Occupational 
Therapist, Dentist, Phlebotomy, Patient Education, Pharmacy, Other 
Facilities Management: Electrician, Environmental Services, Housekeeping, Support Staff 
Medical Doctor/ Doctor of Osteopathy: Attending, Resident 















 1 (referent) 























 1 (referent) 
Native American / 
Pacific Islander 








Smoking    0.33†  










 1 (referent) 
Occupation    0.0028†*  
Administrative 145 
(8.3%) 
7 (4.8%) 138 
(95.2%) 
 1 (referent) 





















25 (1.4%) 0 25 (100%)  0.00 (0.00-
NaN**) 
Medical Doctor / 




















Among the 441 participants with a previous RT-PCR test, 85 (19.3%) were found 
to be positive by RT-PCR, while 350 were negative. Of the RT-PCR positive, 64 (75.3%) 
were also seropositive for IgG but 21 (24.7%) were seronegative. Of the RT-PCR 
negative, 7 were seropositive (2%) for IgG. A total of 1302 participants had no prior RT-
PCR test and of these participants, 23 (1.8%) were positive for SARS-CoV-2 IgG, which 
shows the rate of asymptomatic infection (Table 2). 
 
Table 2. SARS-CoV-2 RT-PCR Result by SARS-CoV-2 IgG Status 




n (row %) 
Negative 
n (row %) 
Total 1743 95 1648 
RT-PCR Tested 441 72 369 
Indeterminate/No result 6 1 (16.7%) 5 (83.3%) 
Negative 350 7 (2.0%) 343 (98.0%) 
Positive 85 64 (75.3%) 21 (24.7%)  
RT-PCR Not Tested 1302 23 (1.8%) 1279 (98.2%) 
 
 
Seropositivity status was significantly associated with self-reported COVID-19 
symptoms of fever, cough, shortness of breath, chills, myalgia, loss of appetite, and loss 
of smell and taste (Table 3). Sore throat, runny nose, nausea/vomiting, diarrhea, 
headache, rash, seizures were not associated with seropositivity of SARS-CoV-2 





Table 3. Self-Reported Symptoms by SARS-CoV-2 IgG Status 
  SARS-CoV-2 IgG Status  
Symptoms Total 
n (column %) 
Positive 
n (row %) 
Negative 
n (row %) 
p-value 
(All Data) 
Total 1743 95 1648  
Fever** 252 (14.5%) 43 (17.1%) 209 (82.9%) p < 0.001†* 
Sore Throat*** 608 (34.9%) 33 (5.4%) 575 (94.6%) p < 0.001* 
Cough 611 (35.1%) 45 (7.4%) 566 (92.6%) 0.02* 
Runny Nose 672 (38.6%) 32 (4.8%) 640 (95.2%) 0.39 
Shortness of Breath 280 (16.1%) 30 (10.7%) 250 (89.3%) p < 0.001* 
Chills 362 (20.8%) 43 (11.9%) 319 (88.1%) p < 0.001†* 
Nausea/Vomiting 318 (18.2%) 16 (5.0%) 302 (95.0%) 0.83 
Diarrhea 409 (23.5%) 26 (6.4%) 383 (93.6%) 0.43 
Headache 869 (49.9%) 49 (5.6%) 820 (94.4%) 0.81 
Rash 73 (4.2%) 3 (4.1%) 70 (95.9%) 0.79† 
Muscle/Joint Pain 566 (32.5%) 56 (9.9%) 510 (90.1%) p < 0.001* 
Loss of Appetite 285 (16.4%) 36 (12.6%) 249 (87.4%) p < 0.001* 
Loss of Smell/Taste 116 (6.7%) 44 (37.9%) 72 (62.1%) p < 0.001* 
Fatigue 815 (46.8%) 64 (7.9%) 751 (92.1%) p < 0.001* 
Seizures 5 (0.3%) 0 5 (100%) 1.00† 
Altered Consciousness 9 (0.5%) 2 (22.2%) 7 (77.8%) 0.08† 
Other Neurological Signs 21 (1.2%) 5 (23.8%) 16 (76.2%) 0.0045†* 
Serious/Chronic Illness 663 (38.0%) 35 (5.3%) 628 (94.7%) 0.89 
† Fisher’s Exact Test, otherwise, Chi Squared 
* Statistically significant when p-value < 0.05 
**Missing data included in analysis due to accounting for 5.2% of responses 
***Missing data included in analysis due to accounting for 5.3% of responses 
Column percentages may not always add up to 100% due to missing data. Missing data not included in 
analysis ranged from 0-1.03% 
 
 After exposure to patients, patient bodily fluids, or patient surroundings, most 
participants reported following the recommended hand hygiene and personal protective 
equipment (PPE). No statistical significance was observed in seropositivity status and 
hand hygiene practices or PPE usage. However, these same practices were not always 
practiced among their peers. Lack of physical distancing among health care workers in 
work areas and break room was associated with seropositivity (p=0.05, p=3x10-3, 
respectively) (Table 4). 
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Table 4. Infection Prevention and Control Measures by SARS-CoV-2 IgG Status 
















Total 1743 95 1648  
Hand hygiene before and after patient 
contact? 
   0.38† 
Always 1598 
(91.7%) 
85 (5.3%) 1513 
(94.7%) 
 
Most of the time 123 (7.1%) 9 (7.3%) 114 
(92.7%) 
 
Occasionally 0 0 0  
Rarely 2 (0.1%) 0 2 (100%)  
Hand hygiene after body fluid 
exposure? 
   0.25† 
Always 1670 
(95.8%) 
89 (5.3%) 1581 
(94.7%) 
 
Most of the time 24 (1.4%) 3 (12.5%) 21 
(87.5%) 
 
Occasionally 0 0 0  
Rarely 7 (0.4%) 0 7 (100%)  
Hand hygiene after contact with 
patient surroundings? 
   0.50† 
Always 1466 
(84.1%) 
85 (5.8%) 1381 
(94.2%) 
 
Most of the time 233 
(13.4%) 
8 (3.4%) 225 
(96.6%) 
 
Occasionally 5 (0.3%) 0 5 (100%)  
Rarely 4 (0.2%) 0 4 (100%)  
PPE when interacting with patients or 
their specimens? 
   0.95† 
Always 1549 
(88.9%) 
85 (5.5%) 1464 
(94.5%) 
 
Most of the time 141 (8.1%) 8 (5.7%) 133 
(94.3%) 
 
Occasionally 7 (0.4%) 0 7 (100%)  
Rarely 12 (0.7%) 0 12 
(100%) 
 





13 (3.9%) 321 
(96.1%) 
 
Most of the time 721 
(41.4%) 










28 (8.0%) 323 
(92.0%) 
 
Physical distancing in break room?    0.003* 
Always 447 
(25.6%) 
14 (3.1%) 433 
(96.9%) 
 
Most of the time 689 
(39.5%) 










22 (9.9%) 200 
(90.1%) 
 
† Fisher’s Exact Test, otherwise, Chi Squared 
* Statistically significant when p-value < 0.05 
Column percentages may not always add up to 100% due to missing data. Missing data not included in 
analysis ranged from 0.17-2.93% 
 
DART Results 
 Of the 35 participants, nearly half were female (45.7%), over age 60 (45.7%), and 
were obese (45.7%). 5 of the participants (14.3%) reported their ethnicity as 
Hispanic/LatinX, while the race distribution was 54.3% Black, 25.7% White, and 14.3% 
Hispanic. None of these demographics were found to have a significant risk for SARS-





Table 5. DART 
Demographics 













Total 35 2 33  


















































BMI    1.00† 
Underweight 
(<18.5 kg/m2) 



























































† Fisher’s Exact Test, otherwise, Chi Squared 
* Statistically significant when p-value < 0.05 
**NaN is Not a Number, unable to divide by 0 
Column percentages may not always add up to 100% due to missing data. Missing data not 
included in analysis was 2.9% 
 
 
Of the 35 total participants, 33 received negative RT-PCR results. DART was in 
agreement for 81.8% of the 33 negative RT-PCR results. However, DART did show 
discordant results for 2 RT-PCR positive specimens (6.1%). In addition, no DART result 
was available for 4 for 4 (12.1%) of the RT-PCR negative participants due to laboratory 
error. Of the 2 RT-PCR positive participants, DART was in agreement for 1, but gave a 
negative result for the other (Table 6).  
Table 6. SARS-CoV-2 RT-PCR Result by DART Result  




n (row %) 
Negative 
n (row %) 
Inconclusive 
n (row %) 
Total 35 3 28 4 
RT-PCR Result     
Negative 33 2 (6.1%) 27 (81.8%) 4 (12.1%) 



























Of the 1,743 BMC healthcare workers included in our analysis, 1,648 were 
negative and 95 were positive for anti-SARS-CoV-2 IgG, making the overall 
seroprevalence 5.5%. Of the 95 IgG positive participants, 23 of them never received a 
RT-PCR test. Thus, these 23 participants make up the 1.8% of our study population with 
prior asymptomatic infections. The demographic risk factors associated with 
seropositivity were obesity and being Hispanic/LatinX. Participants who experienced 
symptoms of fever, sore throat, cough, shortness of breath, chills, muscle or joint pain, 
loss of appetite, loss of smell or taste, or altered consciousness were all more likely to 
have a positive IgG result. In addition, participants who reported not always following 
physical distancing in work areas or break rooms also had an associated higher risk of 
having anti-SARS-CoV-2 IgG antibodies.  
The overall seroprevalence of anti-SARS-CoV-2 IgG of 5.5% seen at Boston 
Medical Center falls in the middle of seroprevalence rates seen at other medical centers in 
not just the United States, but globally. Medical centers around Germany have reported 
seroprevalence rates of between 0.91-1.6% (45-47), while a hospital in the United 
Kingdom reported a seroprevalence among their healthcare workers of 10.1% (48). A 
meta-analysis of 10 different states withing the US reported seroprevalence rates of lower 
than 10% except in New York and Florida, where the prevalence of anti-SARS-CoV-2 
IgG was much higher (49). Self et al. reported 6.0% seroprevalence of healthcare workers 
at 12 medical centers in the US with a similar demographic to what is seen in SIG-
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COVID. This is comparable to our study. However, an asymptomatic seroprevalence of 
2.6% was seen across their healthcare workers, which is higher than what we have seen at 
BMC(50).  
As seen in Table #2, when study participant serology was compared to prior RT-
PCR testing, some discordant results were seen. 24.7% of the RT-PCR positive 
participants were negative for anti-SARS-CoV-2 IgG. This discrepancy may be 
attributable to either false positive RT-PCR results, false negative serology, or that 
samples were collected from these participants either before or after the IgG antibodies 
were present in a detectable concentration.  
We also observed an asymptomatic seroprevalence of 1.8% of them were positive 
for anti-SARS-CoV-2 IgG. This is important because asymptomatic individuals are likely 
to contribute to the spread of the virus as they do not suspect they are infected. 
The vast majority of study participants reported closely following hospital 
infection and prevention measures when in contact with patients or their surroundings 
and specimens. However, those who did not closely follow infection and prevention 
measures including physical distancing in work areas and the break room were 
significantly more likely to test positive for anti-SARS-CoV-2 IgG. This highlights the 
importance of enforcing and following infection prevention recommendations, even 
amongst coworkers.  
This study, to our knowledge, is the first seroprevalence study of anti-SARS-
CoV-2 IgG amongst healthcare workers in the Boston, MA area. With a large study 
population of 1,743 participants working in a medical center that was hit hard by the 
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pandemic, we were able to complete a cross-sectional study that gave us a single 
timepoint of seroprevalence data. The serological assay used has a sensitivity of 93.8% 
and a specificity of 99.4%, and the study itself was conducted in July 2020. As the first 
surge of COVID-19 in the Northeast was between March-May 2020, the time between 
the onset of the first surge and the study makes it likely that these data reflect true 
seroprevalence in the BMC population in July.  
The limitations of SIG-COVID include a much higher study population 
percentage of doctors, nurses, and patient-facing allied health than the true hospital 
population. Although the study team did specifically approach valets and patient transport 
staff, the majority of these healthcare workers remained uninterested in joining the 
cohort. This means that our study was not representative of the hospital population. This 
study is also not representative of the total population as it focuses on healthcare workers, 
which is a potentially high-risk population. Although we only investigated 
seroprevalence of IgG in the healthcare worker population, transmission of disease could 
have occurred outside of the hospital, meaning that this study does not inform nosocomial 
infection rates. In addition, the nature of a cross-sectional study is that it only yields 
information on prevalence of antibodies at one point in time and doesn’t inform longevity 
and durability of IgG.  
This study may be subject to both recall and self-reporting biases. Recall bias 
occurs when a participant is asked to remember information from some time before, as 
we asked our subjects to recall information from 3 months prior to completing the 
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questionnaire. Self-reporting bias may occur when a participants memory differs from 
actual events. 
SIG-COVID assessed the seroprevalence of a large cohort of healthcare workers 
at a safety net hospital in the Boston, MA area. After the availability of IgG 
quantification and IgM qualification assays become available, we intend to fully 
characterize the antibody status of our baseline samples, which have been bio-banked. In 
addition, we are carrying out a longitudinal aspect of SIG-COVID during which we will 
test the serum of 500 participants every 3 months for 1 year to assess IgG and IgM 
longevity and durability.  
 
DART 
 With a total of 35 participants enrolled in the DART study thus far, we have very 
limited data. The study population is split evenly between male and female (54.3 and 
45.7%, respectively). 71.4% of participants are overweight or obese, and the majority are 
not Hispanic/LatinX. Of these 35 participants, the DART device has had 50.0% positive 
agreement and 81.8% negative agreement in comparison with participant clinical RT-
PCR results.  
 Lateral flow antigen testing devices, of which DART is an example, provide an 
alternative route to RT-PCR for COVID-19 testing. RT-PCR testing is the current clinical 
gold standard for a COVID-19 test, but does have limitations due to expense, lack of 
portability, and supply chain issues (51). Regardless, currently there is not enough 
funding or resources to complete PCR testing on everyone, so availability is largely 
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variable due to various factors. Antigen testing is less costly, more portable, and 
potentially good for widespread testing, but lacks the sensitivity and specificity compared 
to PCR tests. RT-PCR tests generally have 80-100% sensitivity, while antigen test 
sensitivity falls within 50-84% (52). However, antigen test sensitivity does improve when 
used for testing symptomatic individuals (44). 
 Although the current DART test doesn’t exhibit optimal diagnostic 
characteristics, it is possibly attributable to a very limited data set. The majority of the 
patients tested using DART have had clinically negative RT-PCR results. Due to the 
timing of changes in study design, we have not been enrolling participant during either 
COVID-19 surge in the Boston area, which has limited both our overall data set and 
enrollment of SARS-CoV-2 RT-PCR positive participants.  
 The initial device was a dipstick and was detecting the spike protein. The second, 
and current, device is a lateral flow cassette and is testing for the nucleocapsid protein.  h 
of these changes caused significant delays in continuing the trial of the device and may 
explain why the positive and negative agreement of DART is low.  As of March 13th, 
2021, there are 6 lateral flow rapid antigen tests that have received EUA approval and 
each of them tests for the nucleocapsid protein antigen from SARS-CoV-2 (53). 
If, after further testing, DART still does not have acceptable test performance, 
additional changes in study design will need to be considered. There is value in testing 
devices that yield poor results, as it prevents waste of resources and stress from wide 
public use of a potentially faulty test.  
 
33 
We plan to continue the testing on this device until we reach a total number of 
120 participants, 60 of them positive for COVID-19 by RT-PCR and 60 of them negative 
for COVID-19 by RT-PCR. Due to the decreased community prevalance of COVID-19 
cases once again in the Boston area, the device will be tested on retrospective discard 
patient nasopharyngeal swabs. This will enable a robust comparison of clinical RT-PCR 
results including variable cycle threshold values, as well as complete the testing of this 
device in a short amount of time.  
Availability of acceptable sensitive and specific antigen tests will help to improve 
widespread testing, potentially allowing the majority of the population to get regular 
testing and improve chances of catching an infection prior to symptom onset. Even with 
less-than-ideal performance characteristics, antigen testing can be utilized for 
epidemiological surveillance which can ultimately help contain the virus. Surveillance 
testing, albeit imperfect, can help monitor real-time infections in community spread. It 
will not capture every case, but it will identify what location might need more public 
health resources and drive public health policy. Furthermore, this will also help to capture 
asymptomatic cases, individuals that presumably don’t develop symptoms but are key 
contributors to virus transmission in the community(54, 55).  
Lack of sensitivity is less tolerable than specificity in the context of SARS-CoV-2 
cases. One can compensate for lack of specificity with reflex testing and lack of 
sensitivity by administering more frequent testing, in addition to capturing individuals at 
the peak of their infections.  It is imperative that rapid antigen testing be part of the 
COVID-19 testing infrastructure coupled with contact tracing and other public health 
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measures to make actionable changes in a timely fashion. Antigen testing is an integral 
part of the equation in controlling the pandemic and will help to curb the spread of 
SARS-CoV-2 while maintaining an affordable price and relieving the strain on resources.  
 
The Role of Testing 
 To further our understanding of the rapidly evolving SARS-CoV-2, it is 
imperative that multiple testing modalities are employed simultaneously. Each 
mechanism of testing provides a different set of clinical data and together they will help 
elucidate information such as transmission, infection, and reinfection rates, as well as 
identify high risk populations.  
 RT-PCR testing is the gold standard for SARS-CoV-2 diagnostics. By amplifying 
the viral genetic material, it provides information on current infection status. Although 
very useful, RT-PCR testing has limitations including expense, turn-around time from a 
few hours to multiple days, supply chain issues, and reagent availability. As such, 
availability of molecular testing varies greatly. Other testing modalities must be 
employed in the context of their performance characteristics.  
 Antigen testing is similar to RT-PCR testing in that they both aim to detect 
current infections. However, antigen testing employs a different mechanism, usually in 
the form of a lateral flow assay. Instead of amplifying the viral genome, it tests directly 
for the virus present in a patient specimen. Because there is no amplification, antigen 
testing has a lower sensitivity than RT-PCR testing, especially in asymptomatic 
individuals. The major draw to this type of testing is that results are available in 15-30 
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minutes and that these devices are inexpensive enough to be considered for frequent at-
home testing. 
 Finally, multiple serology antibody tests have been rapidly developed and granted 
EUA approval, while many more, directed at different epitopes, are continuing to be 
developed. These assess prior exposure and do not provide any information about current 
infection. Antibodies can be produced in response to natural SARS-CoV-2 infection and 
to vaccination. Many studies are currently investigating the levels and durability of these 
antibodies, determining the level necessary to provide protective immunity against severe 
disease and reinfection. Therefore, assessing antibody levels will help to retrospectively 
determine transmission rates, risk factors, and immune response in both vaccinated and 
unvaccinated individuals.  
 Each testing modality works to fill in the gaps of knowledge that still 
persist around SARS-CoV-2. RT-PCR testing is the gold standard diagnostic tool for 
current infections, but alone will not be sufficient to assess the public health burden of the 
pandemic. Rapid antigen testing provides the possibility of extending point of care testing 
to primary care offices, first responders, and even the general public for at-home use. 
Serological testing provides population-based data regarding pathogen exposure by 
accurately quantifying antibodies, facilitating understanding the role of antibodies in 
immunity elicited by both natural and vaccine response and will provide information on 
immunity and antibody durability. Each of these testing types provides a unique piece of 
information and when used together, will help to inform strategies to overcome the 
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